<i id='082140C140'><strike id='082140C140'><tt id='082140C140'><pre id='082140C140'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real
read more
AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s
read more
MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef
read moreBernardMossCourtesyNIAIDFormorethanhalfacentury,scientistBernardMosshasbeencommandingtheattentionofp
